IFNA1 and COVID-19: Here we found evidence for IgG autoantibodies targeting IFN-ω and 11 IFNα subtypes in 1/8 participants who developed severe COVID-19, 0/12 participants with mild or moderate disease, and 0/5 healthy donors (Figure 3I).